Lipid-based formulations for danazol containing a digestible surfactant, labrafil M2125CS: In vivo bioavailability and dynamic in vitro lipolysis

Pharmaceutical Research

Volumn 25, Issue 12, 2008, Pages 2769-2777

  Larsen, Anne ^a   Holm, René ^b   Pedersen, Mette Lund ^b   Müllertz, Anette ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b H LUNDBECK A S   (Denmark)

Author keywords

Labrafil; Lipid based formulations; Lipolysis; Poorly water soluble drugs; Suspensions

Indexed keywords

DANAZOL; DRUG VEHICLE; LIPID; SURFACTANT;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; CONFERENCE PAPER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SOLUBILITY; IN VITRO STUDY; IN VIVO STUDY; LIPOLYSIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUSPENSION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DANAZOL; LIPOLYSIS; MALE; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SURFACE-ACTIVE AGENTS; SUSPENSIONS; VEHICLES;

EID: 57149136074     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-008-9641-0     Document Type: Conference Paper

References (42)

1. K. J. MacGregor J. K. Embleton J. E. Lacy E. A. Perry L. J. Solomon H. Seager C. W. Pouton 1997 Influence of lipolysis on drug absorption from the gastro-intestinal tract Adv. Drug Deliv. Rev 25 33 46
2. A. J. Humberstone W. N. Charman 1997 Lipid-based vehicles for the oral delivery of poorly water soluble drugs Adv. Drug Deliv. Rev 25 103 128
3. C. W. Pouton 2006 Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system Eur. J. Pharm. Sci 29 278 287
4. G. A. Kossena B. J. Boyd C. J. H. Porter W. N. Charman 2003 Separation and characterization of the colloidal phases produced on digestion of common formulation lipids and assessment of their impact on the apparent solubility of selected poorly water-soluble drugs J. Pharm. Sci 92 634 648
5. C. J. H. Porter N. L. Trevaskis W. N. Charman 2007 Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs Nat. Rev. Drug Discov 6 231 248
6. P. J. Carrigan T. R. Bates 1973 Biopharmaceutics of drugs administered in lipid-containing dosage forms I: GI absorption of griseofulvin from an oil-in-water emulsion in the rat J. Pharm. Sci 62 1476 1479
7. S. Chakrabarti F. M. Belpaire 1978 Biovailability of phenytoin in lipid containing dosage forms in rats J. Pharm. Pharmacol 30 330 331
8. R. C. Bravo González J. Huwyler I. Walter R. Mountfield B. Bittner 2002 Improved oral bioavailability of cyclosporin A in male Wistar rats Comparison of a Solutol HS 15 containing self-dispersing formulation and a microsuspension Int. J. Pharm 245 143 151
9. A. Cilek N. Celebi F. Tirnaksiz 2006 Lecithin-based microemulsion of a peptide for oral administration: Preparation, characterization, and physical stability of the formulation Drug Deliv 13 19 24
10. D. J. Hauss S. E. Fogal J. V. Ficorilli C. A. Price T. Roy A. A. Jayaraj J. J. Keirns 1998 Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor J Pharm Sci 87 164 169
11. Z. Hu R. Tawa T. Konishi N. Shibata K. Takada 2001 A novel emulsifier, Labrasol, enhances gastrointestinal absorption of gentamicin Life Sci 69 2899 2910
12. K. Itoh S. Matsui Y. Tozuka T. Oguchi K. Yamamoto 2002 Improvement of physicochemical properties of N-4472. Part II: characterization of N-4472 microemulsion and the enhanced oral absorption Int. J. Pharm 246 75 83
13. H. J. Kim K. A. Yoon M. Hahn E. S. Park S. C. Chi 2000 Preparation and in vitro evaluation of self-microemulsifying drug delivery systems containing idebenone Drug Dev. Ind. Pharm 26 523 529
14. S. Mori A. Matsuura Y. V. R. Prasad K. Takada 2004 Studies on the intestinal absorption of low molecular weight heparin using saturated fatty acids and their derivatives as an absorption enhancer in rats Biol. Pharm. Bull 27 418 421
15. H. Shen M. Zhong 2006 Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin J. Pharm. Pharmacol 58 1183 1191
16. R. G. Strickley 2004 Solubilizing excipients in oral and injectable formulations Pharm. Res 21 201 230
17. J. F. Cuiné W. N. Charman C. W. Pouton G. A. Edwards C. J. H. Porter 2007 Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs Pharm. Res 24 748 757
18. S. Fernandez V. Jannin J. D. Rodier N. Ritter B. Mahler F. Carrière 2007 Comparative study on digestive lipase activities on the self emulsifying excipient LabrasolÒ, medium chain glycerides and PEG esters Biochim. Biophys. Acta 1771 633 640
19. L. Sek B. J. Boyd W. N. Charman C. J. H. Porter 2006 Examination of the impact of a range of pluronic surfactants on the in-vitro solubilisation behaviour and oral bioavailability of lipidic formulations of atovaquone J. Pharm. Pharmacol 58 809 820
20. J. F. Cuiné C. L. McEvoy W. N. Charman C. W. Pouton G. A. Edwards H. Benameur C. J. H. Porter 2008 Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs J. Pharm. Sci 97 995 1012
21. A. Dahan A. Hoffman 2006 Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: Correlation with in vivo data and the relationship to intra-enterocyte processes in rats Pharm. Res 23 2165 2174
22. J. P. Reymond H. Sucker 1988 In vitro model for ciclosporin intestinal absorption in lipid vehicles Pharm. Res 5 673 676
23. L. Sek C. J. H. Porter W. N. Charman 2001 Characterisation and quantification of medium chain and long chain triglycerides and their in vitro digestion products, by HPTLC coupled with in situ densitometric analysis J. Pharm. Biomed. Anal 25 651 661
24. N. H. Zangenberg A. Müllertz H. G. Kristensen L. Hovgaard 2001 A dynamic in vitro lipolysis model II: Evaluation of the model Eur. J. Pharm. Sci 14 237 244
25. C. J. H. Porter A. M. Kaukonen A. Taillardat-Bertschinger B. J. Boyd J. M. O'Connor G. A. Edwards W. N. Charman 2004 Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: Studies with halofantrine J. Pharm. Sci 93 1110 1121
26. C. J. H. Porter A. M. Kaukonen B. J. Boyd G. A. Edwards W. N. Charman 2004 Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation Pharm. Res 21 1405 1412
27. A. Dahan A. Hoffman 2007 The effect of different lipid based formulations on the oral absorption of lipophilic drugs: The ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats Eur. J. Pharm. Biopharm 67 96 105
28. E. A. Gad Kariem M. A. Abounassif M. E. Hagga H. A. Al-Khamees 2000 Photodegradation kinetic study and stability-indicating assay of danazol using high-performance liquid chromatography J. Pharm. Biomed. Anal 23 413 420
29. J. O. Christensen K. Schultz B. Mollgaard H. G. Kristensen A. Mullertz 2004 Solubilisation of poorly water-soluble drugs during in vitro lipolysis of medium- and long-chain triacylglycerols Eur. J. Pharm. Sci 23 287 296
30. N. H. Zangenberg A. Müllertz H. G. Kristensen L. Hovgaard 2001 A dynamic in vitro lipolysis model I. Controlling the rate of lipolysis by continuous addition of calcium Eur. J. Pharm. Sci 14 115 122
31. W. N. Charman M. C. Rogge A. W. Boddy B. M. Berger 1993 Effect of food and a monoglyceride emulsion formulation on danazol bioavailability J. Clin. Pharmacol 33 381 386
32. V. H. Sunesen R. Vedelsdal H. G. Kristensen L. Christrup A. Müllertz 2005 Effect of liquid volume and food intake on the absolute bioavailability of danazol, a poorly soluble drug Eur. J. Pharm. Sci 24 297 303
33. S. I. F. Badawy M. M. Ghorab C. M. Adeyeye 1996 Characterization and bioavailability of danazol-hydroxypropyl b-cyclodextrin coprecipitates Int. J. Pharm 128 45 54
34. V. Bakatselou R. C. Oppenheim J. B. Dressman 1991 Solubilization and wetting effects of bile-salts on the dissolution of steroids Pharm. Res 8 1461 1469
35. R. L. Barbieri K. J. Ryan 1981 Danazol: Endocrine pharmacology and therapeutic applications Am. J. Obstet. Gynecol 141 453 463
36. C. Y. Wu L. Z. Benet 2005 Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system Pharm. Res 22 11 23
37. M. Devani M. Ashford D. Q. M. Craig 2004 The emulsification and solubilisation properties of polyglycolysed oils in self-emulsifying formulations J. Pharm. Pharmacol 56 307 316
38. T. R. Bates J. A. Sequeria 1975 Bioavailability of micronized griseofulvin from corn oil-in-water emulsion, aqueous suspension, and commercial tablet dosage forms in humans J. Pharm. Sci 64 793 797
39. H. H. Hölzer C. M. Turkelson T. E. Solomon H. E. Raybould 1994 Intestinal lipid inhibits gastric-emptying via CCK and a vagal capsaicin-sensitive afferent pathway in rats Am. J. Physiol. Gasterointest. Liver Physiol 30 G625 G629
40. F. Seeballuck E. Lawless M. B. Ashford C. M. O'Driscoll 2004 Stimulation of triglyceride-rich lipoprotein secretion by polysorbate 80: In vitro and in vivo correlation using Caco-2 cells and a cannulated rat intestinal lymphatic model Pharm. Res 21 2320 2326
41. A. M. Kaukonen B. J. Boyd C. J. H. Porter W. N. Charman 2004 Drug solubilization behavior during in vitro digestion of simple triglyceride lipid solution formulations Pharm. Res 21 245 253
42. FDA. Guidance for Industry: Extended release oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Rockville, MD, 1997.